NASDAQ · SNDX
Healthcare · Biotechnology
$18.09
Down-$0.81 (-4.48%)
Updated Sep 16, 2026, 9:44 PM
SID Score
3.2/10
Composite research score
Smart Money
—
Institutional and insider signal
Price performance
1M range · 20 trading sessions · Daily adjusted prices
SNDX closed at $18.09 after 20 trading sessions, down 9.16% for the selected period.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Sep 15, 2026 | $18.19 | $18.19 | $17.71 | $18.09 | 1.13M |
| Sep 14, 2026 | $18.30 | $18.68 | $18.235 | $18.35 | 1.19M |
| Sep 11, 2026 | $19.01 | $19.02 | $18.02 | $18.18 | 1.22M |
| Sep 10, 2026 | $19.67 | $19.69 | $18.40 | $18.82 | 1.65M |
| Sep 9, 2026 | $19.82 | $20.205 | $19.69 | $19.84 | 1.24M |
| Sep 8, 2026 | $20.19 | $20.48 | $19.90 | $19.94 | 1.21M |
| Sep 4, 2026 | $20.46 | $21.00 | $20.46 | $20.56 | 1.36M |
| Sep 3, 2026 | $20.85 | $20.99 | $20.54 | $20.68 | 1.92M |
| Sep 2, 2026 | $20.23 | $21.00 | $19.965 | $20.78 | 2.02M |
| Sep 1, 2026 | $19.29 | $20.15 | $19.09 | $20.10 | 1.41M |
| Aug 31, 2026 | $19.44 | $19.46 | $19.00 | $19.29 | 1.4M |
| Aug 28, 2026 | $19.98 | $20.045 | $19.47 | $19.54 | 1.04M |
| Aug 27, 2026 | $20.01 | $20.23 | $19.70 | $20.16 | 652.36K |
| Aug 26, 2026 | $19.92 | $20.22 | $19.60 | $20.09 | 789.97K |
| Aug 25, 2026 | $19.73 | $20.40 | $19.70 | $19.92 | 975K |
| Aug 24, 2026 | $19.70 | $19.87 | $19.17 | $19.57 | 1.44M |
| Aug 21, 2026 | $19.93 | $20.28 | $19.25 | $19.65 | 1.7M |
| Aug 20, 2026 | $20.39 | $20.72 | $19.64 | $19.75 | 1.12M |
| Aug 19, 2026 | $20.67 | $20.875 | $20.01 | $20.77 | 1.19M |
| Aug 18, 2026 | $19.83 | $20.10 | $19.67 | $19.915 | 1.02M |
The latest Smart Investors Daily articles mentioning SNDX.
SNDX research
Company profile and research snapshot.
Syndax Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on developing a pipeline of combination therapies in multiple cancer indications. Its product candidates include revumenib and axatilimab. It is developing revumenib, a selective menin-MLL inhibitor for KMT2A-rearranged (MLL-r) and NPM1-mutant acute leukemias, including ALL and AML. It is also developing axatilimab, a CSF-1R-blocking antibody for cGVHD and idiopathic pulmonary fibrosis. Entinostat is its oral, small molecule product candidate that has direct effects on both cancer cells and immune regulatory cells. The business activity of the group is functioned through the region of the United States.
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| Aug 21, 2026 | UBS | Buy | — |
| Aug 11, 2026 | JP Morgan | Overweight | — |
| Aug 5, 2026 | HC Wainwright & Co. | Buy | — |
| Jul 15, 2026 | HC Wainwright & Co. | Buy | — |
| Jun 12, 2026 | HC Wainwright & Co. | Buy | — |
No generated briefing is available yet.
SeekingAlpha · Sep 10, 2026
Syndax Pharmaceuticals, Inc. (SNDX) Citigroup's Biopharma Back to School Summit 2026 September 10, 2026 8:40 AM EDTCompany ParticipantsMichael Metzger - CEO...
Yahoo · Sep 4, 2026
NEW YORK, Sept. 04, 2026 (GLOBE NEWSWIRE) -- Syndax Pharmaceuticals (Nasdaq: SNDX), a commercial-stage biopharmaceutical company advancing innovative cancer therapies, today announced that on September 1, 2026, the Company granted inducement awards to purchase up to 175,000 shares of common stock to nineteen new employees under the Company's 2023 Inducement Plan. The stock options will vest over four years, with 25% of the underlying shares vesting on the one-year anniversary of the vesting comm
Yahoo · Sep 1, 2026
NEW YORK, Sept. 01, 2026 (GLOBE NEWSWIRE) -- Syndax Pharmaceuticals (Nasdaq: SNDX), a commercial-stage biopharmaceutical company advancing innovative cancer therapies, today announced that Michael A. Metzger, Chief Executive Officer, as well as members of the Syndax management team, will participate in the following upcoming investor conferences: Citi 2026 Biopharma Back to School Conference in New York, NY with a fireside chat on Thursday, September 10, 2026, at 8:40 a.m. ET.H.C. Wainwright 28t
Yahoo · Aug 22, 2026
With the third quarter well underway and most second-quarter earnings now in the rearview mirror, investors are starting to look ahead to the rest of 2026 and how best to position their portfolios.Summer Sale - Claim 70% Off TipRanks Unlock powerful investing tools with TipRanks Premium to make smarter, more confident investment decisions Subscribe to TipRanks Smart Investor Newsletter, and discover new investing opportunities with data-backed stock picks The good news is that the latest earning
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning SNDX.
